Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC +1.20%97 Earnings Yield (Joel Greenblatt) % is 5.60% as of Jun. 2026, which is 50% above its 10-year median of 3.74. GuruFocus rates CHIX:GMABC with a GF Score™ of 97/100 and a GF Value™ of kr2,295.14 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,345 Biotechnology companies, Genmab AS ranks better than 90.33% on this metric.
Genmab AS's Enterprise Value for the quarter that ended in Jun. 2026 was kr127,162 Mil.
Genmab AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was kr7,547 Mil. Genmab AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 5.60%.
The historical rank and industry rank for Genmab AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CHIX:GMABc'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 1 Med: 3.74 Max: 16.35
Current: 4.82
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Genmab AS was 16.35%. The lowest was 1.00%. And the median was 3.74%.
CHIX:GMABc's Earnings Yield (Joel Greenblatt) % is ranked better than 90.33% of 1345
companies
in the Biotechnology industry
Industry Median: -9.94
vs CHIX:GMABc: 4.82
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Genmab AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 24.38%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Genmab AS (CHIX:GMABc) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Genmab AS Earnings Yield (Joel Greenblatt) % Related Terms
Genmab AS Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Genmab AS's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Genmab AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Genmab AS's Earnings Yield (Joel Greenblatt) % falls into.
Genmab AS Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Genmab ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Genmab AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7,547 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 5.60% mean?
Genmab AS (CHIX:GMABC) has a Earnings Yield (Joel Greenblatt) % of 5.60% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Genmab AS and its competitors. This is 50% above median its historical median of 3.74. Over the past decade, Genmab AS's Earnings Yield (Joel Greenblatt) % has ranged from 1.00 to 16.35. According to the industry distribution chart, Genmab AS ranks #130 out of 1345 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Genmab AS's Earnings Yield (Joel Greenblatt) % too high?
Genmab AS's current Earnings Yield (Joel Greenblatt) % of 5.60% is 50% above median its 10-year median of 3.74. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 16.35. Based on the distribution chart, Genmab AS ranks #130 out of 1345 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #130 out of 1345 companies for Earnings Yield (Joel Greenblatt) %. This places Genmab AS in the top 10% of its industry — outperforming the majority of peers. Historically, Genmab AS's own Earnings Yield (Joel Greenblatt) % has ranged from 1.00 to 16.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Genmab AS and its competitors. Genmab AS's current Earnings Yield (Joel Greenblatt) % is 5.60%, which is 50% above median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,295.14, compared to a current price of kr2,154.00 — trading 6.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 5.60%, which is 50% above median its 10-year median of 3.74. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Earnings Yield (Joel Greenblatt) % is 5.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr2,154.00 is trading 6.1% below its estimated GF Value™ of kr2,295.14.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
Earnings Yield (Joel Greenblatt) %: 5.60% (50% above median its 10-year median of 3.74)
GF Value™: kr2,295.14 vs. price of kr2,154.00 (6.1% below fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score
Get the complete analysis for CHIX:GMABC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
